There are data to suggest the existence of non-Helicobacter pylori gastritis. However, the risk factors and clinical course for H pylori-negative gastritis remain unclear. We aimed to examine the prevalence and determinants of H pylori-negative gastritis in a large multiethnic clinical population.
G astritis is a common inflammatory condition of the gastric mucosa. The extent and distribution of gastritis are related to its cause and host responses. 1 Epidemiologic data have consistently indicated that Helicobacter pylori-associated gastric inflammation and atrophy are associated with the risk of gastric adenocarcinoma. 2, 3 Worldwide, H pylori are the major cause of active and chronic gastritis, and development and recurrence of peptic ulcer disease, atrophic gastritis, and gastric cancer. 4 The overall incidence of noncardia gastric cancer and gastric ulcer has steadily declined in the United States in correlation with declining H pylori infection rates over the past 50 years 5 ; however the incidence of this cancer has unexpectedly increased among persons born after 1952. 6 It remains unclear whether this is related to an increase in gastric cancer caused by an undefined risk factor or by an increased prevalence of individuals emigrating from high-risk regions. 7, 8 There are earlier reports that suggest the existence of non-H pylori gastritis. 9, 10 In a previous study, we examined the presence, type, and pattern of gastritis in 491 patients and found gastritis in 40.7% of these patients, of whom 20.5% were H pylori-negative by histopathology, serology, and culture (8.4% in total study sample). 11 Among the 41 patients in this study with H pylori-negative gastritis, 73.2% had chronic gastritis, 12.2% had active gastritis, and the remaining 14.6% had both. In another study, H pylori-negative gastritis defined by histopathology alone was reported in 1.5% of patients from a large national pathology database consisting primarily of insured patients (12% of those with gastritis). 9 These preliminary data support the concept that H pylori-negative gastritis is likely a real condition most likely unrelated to current or past H pylori infection. However, those findings were limited in scope, and the risk factors, clinical course, and impact of H pylori-negative gastritis remain unclear.
This study used uniform testing for H pylori using histopathology, culture, and serum antibodies to both H pylori and CagA to identify a cohort of patients with H pylori-negative gastritis, and to examine for possible risk factors and clinical manifestations of H pylori-negative gastritis.
Methods

Study Population
We used data from a cross-sectional study conducted at the Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC) in Houston, Texas between March 2009 and August 2013 that examined risk factors for several gastrointestinal disorders. 12 The current study did not overlap with the prior study that encompassed February 15, 2008 , to February 18, 2009 . 12 In brief, consecutive eligible patients who were scheduled for an elective esophagastroduodenoscopy (EGD) at MEDVAMC were invited to participate in the study. The study also included randomly selected and recruited patients eligible for screening colonoscopy from 7 selected primary care clinics at the same hospital. After consenting to the study, these patients were then scheduled and underwent the study EGD at the same time as their screening colonoscopy. Study eligibility was based on the following: age between 40 and 80 years; no previous surgical resection of the esophagus or stomach; no previous cancer of the esophagus, lung, liver, colon, breast, or stomach; no current use of anticoagulants; no significant liver disease; and no history of major stroke or mental condition that would limit ability to answer questions. Informed consent was obtained from all participants, and this study was approved by the institutional review board at Baylor College of Medicine and Research and Development at MEDVAMC.
Endoscopy and Biopsies
Endoscopic findings, including gastric or duodenal ulcers, were systematically recorded in all patients.
Gastric mapping was performed by taking 7 mucosal biopsy samples from the antrum (from the greater curvature and from the lesser curvature), the corpus (from the distal greater curvature, distal lesser curvature, proximal greater curvature, and proximal lesser curvature), and the cardia. In addition, at least 1 gastric biopsy was collected from the lesser curvature of the antrum from all study subjects and placed in sterile vials, containing cysteine medium with 20% glycerol and stored at À80 C until cultured for H pylori.
Helicobacter pylori Culture
Frozen specimens were thawed, and the tissues were homogenized and inoculated onto 2 types of selective media: Brain Heart Infusion and H pylori Special Peptone Agar plates with 7% horse blood. The plates were incubated for up to 14 days at 37 C under microaerophilic conditions (5% O 2 , 10% CO 2 , and 85% N 2 ) in an Anoxomat jar. Positive growth was transferred to a fresh, nonselective Brain Heart Infusion blood agar plate and incubated for 48-72 hours. H pylori were identified when the oxidase, catalase, and urease reactions were positive with a compatible Gram stain. We selected and subcultured several small round colonies from each patient's plate 1 or 2 times to obtain a pure culture. The isolated strains were then stored at À80 C in cysteine storage medium containing 20% glycerol.
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Histopathologic Examination
All biopsy specimens were embedded in paraffin, oriented on edge, sectioned in 5-m sections, and stained with hematoxylin and eosin, alcian blue at pH 2.5; and in case of negative staining for H pylori, a modified silver stain; and alcian blue-periodic acid Schiff stain. Two gastrointestinal pathologists (M.R. and G.V.), who were blinded to the other H pylori test results, identified H pylori microorganisms and graded features of gastritis, gastric atrophy, and intestinal metaplasia on each biopsy according to the standardized Updated Sydney System. 3 Equivocal cases were further examined using immunostaining for H pylori. Disagreements between the 2 pathologists were settled by a third pathologist (L.G.). Gastritis was defined by the presence of at least grade 2 neutrophils or mononuclear cells in at least 1 gastric biopsy site, or grade 1 neutrophils or mononuclear cells in at least 2 gastric sites. 11 Nongastritis was defined as all grade 0 for neutrophils or mononuclear cells in all gastric biopsy sites. Severity and extent of atrophy was evaluated by Operative Link for Gastritis Assessment (OLGA) staging. 15 
Serology
We evaluated serum samples for H pylori IgG antibody, using an enzyme-linked immunosorbent assay (BIOHIT HealthCare, Helsinki, Finland), and defined positive results as !30 enzyme immunoassay unit or optical density of >2. According to the manufacturer, this test has 96.5% sensitivity and 96.0% specificity compared with culture, and this test ranked second in terms of accuracy (>94%) in a comparative study of 29 commercially available tests. 16 We measured serum antiCagA IgG antibody using a commercially available enzyme-linked immunosorbent assay kit (Genesis Diagnostics Ltd, Cambridgeshire, UK) with !6.25 U/mL to define positivity. According to the manufacturer, the test has 96.3% sensitivity and 96.7% specificity compared with Western blot.
Survey Questionnaire
Before the study EGD, all study participants completed a computer-assisted survey and had anthropometric measurements taken. The survey ascertained lifetime history and current use of alcohol and smoking; medical history (including previous treatment for H pylori); frequency and severity of heartburn and acid regurgitation symptoms; and use of medications, such as proton pump inhibitors (PPIs), histamine-2 receptor antagonists, and nonsteroidal anti-inflammatory drugs (NSAIDs). Height, weight, and waist and hip circumferences were measured for all study participants and we calculated body mass index and waist-to-hip ratio. We used standard categories for body mass index (<25, 25 to <30, !30 kg/m 2 ) and waist-to-hip ratio was categorized as high if it was 0.9 or greater for men or 0.85 or greater for women (high risk vs low risk). Frequency of gastroesophageal reflux disease (GERD) symptoms was defined as the highest reported frequency of either heartburn or acid regurgitation symptoms; "frequent symptoms" were those occurring at least weekly.
Chart Reviews
We reviewed the entire Veterans Health Administration medical records for all study patients from date of first visit to the last visit through December 2014. We searched for H pylori tests (serology, urea breath test, and stool antigen test) and H pylori treatment. In the patients with H pylori-negative gastritis, we searched for history of inflammatory bowel disease including Crohn's disease, or ulcerative colitis, autoimmune gastritis, sarcoidosis, eosinophilic gastritis, and lymphocytic gastritis. Lastly, we looked for all endoscopic examinations and recorded findings (erosive esophagitis, Barrett's esophagus, and gastric or duodenal ulcers, erosions, or cancers).
Helicobacter pylori Status
H pylori-negative status was determined when all 5 of the following criteria were fulfilled: (1) a negative histopathology, (2) a negative H pylori culture, (3) a negative IgG H pylori serology, (4) negative IgG antibodies to CagA, and (5) no self-reported or medicalrecord documentation for previous H pylori treatment. However, H pylori-positive status was determined when both of these 2 criteria were fulfilled: a positive staining of gastric mucosa in at least 1 of 7 biopsy sites (hematoxylin and eosin, alcian blue at pH 2.5, and a modified silver stain); and a positive H pylori culture. We did not consider positive serology alone because these tests may not reflect active infection.
Statistical Analysis
We compared patients with H pylori-negative gastritis separately with those with H pylori-positive gastritis, and those with H pylori-negative nongastritis. We compared the demographic and clinical features, including symptoms and endoscopic findings, and possible risk or protective factors, including smoking status, and use of aspirin, NSAIDs, and PPIs, between the groups using chi-square test for categorical variables and Student t tests for continuous variables. We also compared the proportions with antrum or corpus neutrophils (active) or mononuclear cells (chronic), antrum or corpus atrophy or intestinal metaplasia. We examined possible predictors of H pylori-negative gastritis using multivariable logistic regression models. Except for age (categorical: <60, !60 years), sex, and race (3 categories: non-Hispanic white, African American, other), which were forced into the final models, variables were included in the final multivariable model using a P value cutoff of 0.25 in univariate analysis. For each variable, the odds ratio (OR) and 95% confidence interval (CI) were calculated.
In supplemental analyses, for each endoscopic finding (Barrett's esophagus, gastric ulcers, and so forth) on EGDs performed before or after the study EGD, we calculated the incidence rate as the number of events divided by total person-years of follow-up. Time of follow-up was calculated from the date of first visit to the date of last visit (or date of study EGD). We estimated hazard ratios (HR) and corresponding 95% CI for the individual clinical symptoms and endoscopic findings using Cox proportional hazards models.
All statistical analyses were performed using SPSS version 19 (SPSS Inc, Chicago, IL) and a 2-tailed P < .05 was considered statistically significant.
Results
During the study period, 2244 patients agreed to participate in the study. A total of 1701 underwent the study EGD and 1240 had information from all biopsy sites and were included in the current study. Of these, 695 (56.0%) patients met our criteria for gastritis ( Figure 1 ). Among 319 patients that met our criteria for gastritis and were negative for H pylori in all 7 biopsy sites, we excluded 196 who did not meet our strict criteria for H pylori-negative status (self-reported prior diagnosis of H pylori Figure 1 ). Likewise, among the 376 patients that met our criteria for gastritis but were H pylori-positive in at least 1 site, we excluded 169 (suspicious positive, prior eradication, culture negative, no culture data, or other) and classified the remaining 207 as definite for H pylori-positive gastritis. Among the 545 patients that did not meet the criteria for gastritis, 420 (33.9% of the 1240 study population) had grade of 0 for neutrophils or mononuclear cells in all gastric biopsy site. Of these 420 patients, we excluded 239 who did not meet our strict criteria for H pylori-negative status and classified 181 of these patients as being definite for H pylorinegative nongastritis ( Figure 1 ).
Helicobacter pylori-Negative Gastritis Versus Helicobacter pylori-Positive Gastritis
Compared with patients with H pylori-positive gastritis, those with H pylori-negative gastritis were statistically significantly less likely to be male and African American, but more likely to have a history of PPI use and frequent GERD symptoms (Table 1 ). In multivariate analysis comparing H pylori-negative gastritis and H pylori-positive gastritis patient groups, nonwhite race (vs non-Hispanic white: OR for African American, 0.25; 95% CI, 0.14-0.43; OR for other race, 0.39; 95% CI, 0.18-0.82) and ever use of PPIs (vs nonusers of PPIs: OR, 2.02; 95% CI, 1.17-3.49) remained statistically significantly associated with risk of H pylori-negative gastritis (Table 2) .
Helicobacter pylori-Negative Gastritis Versus Helicobacter pylori-Negative Nongastritis
Compared with patients with H pylori-negative nongastritis, those with H pylori-negative gastritis were less likely to be non-Hispanic white and have a history of PPI and NSAID use (Table 1 ). In multivariate analysis comparing patients with H pylori-negative gastritis with patients with H pylori-negative nongastritis, older age (!60 vs <60 years; OR, 1.98; 95% CI, 1.06-3.69) and nonwhite race (vs non-Hispanic white: OR for African American, 1.78; 95% CI, 0.94-3.40; OR for other race, 4.70; 95% CI, 1.59-13.85) were associated with increased risk of H pylori-negative gastritis (Table 2) . However, compared with never users of these classes of medication, ever users of NSAIDs (OR, 0.43; 95% CI, 0.25-0.76) and PPIs (OR, 0.57; 95% CI, 0.33-0.97) were less likely to have H pylorinegative gastritis than H pylori-negative nongastritis. 
Histologic Findings
Most gastritis in the H pylori-negative gastritis group was chronic (Figure 2A and B), whereas both active and chronic were present in most cases with H pyloripositive gastritis (Table 3 ). In the H pylori-negative gastritis group, most of these (85 of 123; 69.1%) had mononuclear cells of grade 1 in at least 2 sites (ie, no neutrophils). Furthermore, the proportion cases with at least grade 2 for acute or chronic, gastric atrophy, and intestinal metaplasia in any site were significantly higher in the H pylori-positive gastritis group than the H pylorinegative gastritis group. Gastric atrophy and intestinal metaplasia were each found in 13% of patients with H pylori-negative gastritis. Updated Sydney score for gastric atrophy was significantly higher in the H pyloripositive gastritis group than the H pylori-negative gastritis group (0.78 AE 1.73 vs 0.17 AE 0.79; P < .001). OLGA score of III or more was found in 2 (1.6%) subjects in H pylori-negative gastritis group and in 17 (8.2%) of H pylori-positive gastritis group (P < .001).
Endoscopic Findings on the Study Esophagastroduodenoscopy
Compared with H pylori-positive gastritis, the prevalence of Barrett's esophagus was significantly higher in the patients with H pylori-negative gastritis (20.3% vs 13.7%; P ¼ .04) (Table 4 ). However, after adjusting for age, sex, and race, Barrett's esophagus was not statistically significantly associated with H pylori-negative gastritis (OR, 1.44; 95% CI, 0.75-2.78). There were no differences in other endoscopic findings between patients with H pylori-negative gastritis and H pylori-negative nongastritis.
Supplemental Analyses
In addition to the study EGD, a total 174 patients (41 H pylori-negative gastritis, 71 H pylori-negative nongastritis, and 62 H pylori-positive gastritis group) had at least 1 additional EGD with a mean number of EGD of 1.94 AE 1.78. The incidence of endoscopic findings between first visit and last visit was compared between the H pylori-negative gastritis and H pylori-negative nongastritis groups. The incidence of gastric erosions was significantly higher in the H pylori-negative gastritis group than H pylori-negative non-gastritis (30.1 vs 22.0 per 1000 person-years; HR, 1.64; 95% CI, 1.05-2.54) ( Table 5 ). Gastric ulcer was more frequent in H pylorinegative gastritis than H pylori-negative nongastritis group, although it did not reach statistical significance (3.2 vs 1.9 per 1000 person-year; HR, 2.67; 95% CI, 0.65-10.91). After adjusted by age, sex, and race, H pylori-negative gastritis was significantly associated with the incidence of gastric erosions (adjusted HR, 1.64; 95% CI, 1.06-2.56).
The incidence of endoscopic findings in the H pylori-negative and H pylori-positive gastritis groups was examined in the time period between first Veterans Affairs visit to study EGD because H pylori-positive gastritis group was very likely to receive H pylori eradication therapy after study EGD. The incidence of Barrett's esophagus was significantly higher in the H pylori-negative gastritis than H pylori-positive gastritis group (30.2 vs 16.1 per 1000 person-year; HR, 1.95; 95% CI, 1.12-3.41) ( Table 5 ). However, after adjusted by age, sex, and race, the association with Barrett's esophagus did not reach statistical significance (adjusted HR, 1.59; 95% CI, 0.88-2.86). The incidence of gastric ulcer or gastric erosions was not different among 2 groups.
Most of the H pylori-negative gastritis group (85 of 123; 69.1%) had mononuclear cells of grade 1 in at least 2 sites (ie, no neutrophils). Thirty-eight patients showed severe gastritis (ie, neutrophil infiltration or at least grade 2 for mononuclear cells). Therefore, we performed Tables 2 and 3) . The results were similar to the overall pooled analysis, although the number of PPI users was smaller in the primary care group.
Discussion
This study confirms the presence of H pylori-negative gastritis as a common and independent from H pylori gastritis. H pylori-negative gastritis was present in 9.9% of all study subjects and 17.6% of patients with gastritis. Most cases were chronic nonactive gastritis, and although the severity of gastric damage was less than that of H pylori, gastric atrophy and metaplasia were present in 13.0% of cases. The cumulative incidence of gastric erosions and ulcers were higher in patients with H pylori-negative gastritis than H pylori-negative nongastritis. Commonly examined lifestyle factors (smoking, alcohol) and medications (NSAIDs, aspirin, histamine-2 receptor antagonists) were not associated with H pylori-negative gastritis. Although PPI use was more prevalent in H pylori-negative than H pyloripositive gastritis it is unlikely to be a major etiologic risk factor for this entity.
The prevalence of H pylori-negative gastritis in this study was comparable with our previous study (8.4% in total study sample), 11 and although subjects in both studies were from the same sampling frame none of the subjects overlapped. The current study has additional advantages including the larger sample size, the uniform testing for H pylori among all cases and control subjects including those without gastritis, and the evaluation of cumulative history of endoscopic findings. In this study, we used uniform testing for H pylori using histopathology, culture, and serum antibodies to both H pylori and CagA to identify 3 groups of patients (H pylori-negative gastritis, H pylori-positive gastritis, and H pylorinegative nongastritis). In this study, the racial distribution of patients in the 3 groups of gastritis further suggests that H pylori-negative gastritis is a different and distinct entity. African Americans comprised 17.7% of nongastritis, 27.6% of H pylori-negative gastritis, and 56.5% of H pylori-positive gastritis groups. If H pylorinegative gastritis were a result of spontaneous or treatment-related disappearance of this bacterium, the percentage of African American should be comparable between H pylori-negative gastritis and H pylori-positive gastritis.
Histologic examination alone proved insufficient to define H pylori-negative gastritis. Using histopathology alone, 319 patients had gastritis without H pylori. However, 162 of these patients were considered as H pyloripositive by at least 1 additional method (Figure 1 ). We propose that multiple and consistent testing strategy is essential to define H pylori-negative gastritis. However, the prevalence of antibody positivity was low (12.1%) among patients with H pylori-negative nongastritis after excluding patients with H pylori by histology, questionnaires, and bacterial culture. This finding suggests that some patients with previously treated or spontaneously cleared infection would have been included among the nongastritis control patients in this control group had we not performed the serology testing in all groups. CagA antibodies may be positive in patients who have a negative H pylori serologic test 17, 18 and can also remain positive for a longer period of time than the anti-H pylori antibody 19, 20 after successful eradication therapy or spontaneous disappearance. CagA antibody testing in this study resulted in the additional exclusion of 4 patients from H pylori-negative gastritis group, and 3 patients from H pylori-negative nongastritis group.
Long-term PPI use in mice can lead to gastric inflammation, possibly through microbial overgrowth. 21 In our study, PPI use was more likely to be present in the group with H pylori-negative gastritis than H pylori-positive gastritis. However, the percentage of PPI use was highest in H pylori-negative nongastritis. PPI also can reduce the density of H pylori on histologic examination 13, 22 and thus causes false H pylori-negative gastritis on histopathologic examination. However, PPI use does not affect H pylori or CagA antibody titer, and less likely to affect culture results, 13 which were uniformly tested in our study. Therefore, our combined data do not support a causative link between PPI use and H pylori-negative gastritis. In addition, ever use of NSAIDs was associated with H pylori-negative nongastritis than H pylori-negative gastritis. Furthermore, the type of histologic gastropathy caused by NSAIDs is different from those by H pylori infection. These suggest that NSAID use is unlikely to be a major etiologic risk factor for H pylori-negative gastritis.
Although the overall prevalence of significant endoscopic findings seen during a single study endoscopy was not different among 3 groups, the cumulative incidence of gastric erosions or gastric ulcers was significantly higher in the H pylori-negative and positive gastritis than H pylori-negative nongastritis. The incidence of gastric erosions and gastric ulcers was not statistically different between H pylori-negative and H pylori-positive gastritis, which suggests that the potential for the development of clinically significant gastric lesions is elevated in the H pylori-negative gastritis.
Although the histologic precursors of gastric adenocarcinoma (ie, gastric atrophy and or intestinal metaplasia) were present in 13.0% of H pylori-negative gastritis, the histologic scores for these lesions, and for gastritis, were lower than those seen in H pylori-positive gastritis. OLGA staging score for atrophy was also lower in H pylori-negative gastritis than H pylori-positive gastritis. H pylori-negative gastritis was antrum dominant, whereas H pylori-positive gastritis was present equally in the antrum and corpus. We previously reported that all invasive or intraepithelial gastric neoplasia were consistently associated with high-risk OLGA stages (III, IV), 23 whereas low-stage gastritis is associated with low risk of gastric cancer. 24 Therefore, the potential for gastric cancer development in H pylorinegative gastritis needs to be considered but it might well be lower than for those with H pylori-positive gastritis, because H pylori gastritis is also typically a progressive disease. The natural history of H pylorinegative gastritis remains unstudied.
Not all patients with gastric cancer have detectable H pylori infection even with the use of multiple testing modalities (eg, seroprevalence of H pylori IgG antibodies [enzyme-linked immunosorbent assay] or CagA [immunoblot] was 73% in gastric cardia cancer, 96%-97% in noncardia cancer). 18 Most of these patients have extensive atrophy and achlorhydria and the current assumption is that H pylori disappeared over time in these patients. It is also possible that it was absent all along. Achlorhydric gastrin-deficient mice develop overgrowth of bacteria other than Helicobacter species that are associated with the development of chronic atrophic gastritis and progression to gastric cancer. 21, 25 However, gastric cancer is rare in patients with autoimmune gastric atrophy unless H pylori infection is also present. 26 The microbiome of H pylori-negative gastritis is unstudied. Using conventional culture methods, large numbers of acid-resistant bacterial strains exist in the stomach, many of which are derived from transient flora in the mouth, including Streptococcus, Neisseria, and Lactobacillus.
27 However, many non-H pylori microbes could become resident flora in the stomach, and this mucosa-associated microbiota is relatively stable. 28 These microbiota and its metabolites can affect the host directly, a characteristic of organisms related to the pathogenesis of disease.
This study has some limitations. This study is a single Veterans Affairs center based study and although 7.2% of study subjects were female, the generalizability to women and nonveterans is not clear. Although the prevalence of endoscopic findings was estimated from a study endoscopy with systematic recording of findings, the incidence of these findings was based on endoscopic examinations performed for clinical indications rather than a systemic periodic evaluation. Endoscopy may be more readily or frequently performed among patients with positive H pylori tests, and this ascertainment bias, if any, would lead to an increase in endoscopic findings in that group and would make our findings of lack of differences between H pylori-positive and H pylorinegative even more conservative. It is not possible to discern the effect of treatment, such as PPI, on the prevalence and incidence of endoscopic findings; however, if anything the H pylori-negative gastritis group had a higher proportion of PPI users and thus lower likelihood of having peptic erosions and ulcers. Lastly, our study may suffer from selection bias. Of 207 H pyloripositive gastritis patients, 107 (51.7%) were screening colonoscopy patients; the corresponding fractions among H pylori-negative gastritis and H pylori-negative nongastritis patients were 45 (36.6%) and 50 (27.6%), respectively. However, even in subgroup analysis by the source of population, the main results were the same, although the number of PPI use and frequency of GERD symptoms were small in the primary care group. None of the primary care group were primarily referred for EGD and were generally representative of all veterans attending primary care at MEDVAMC.
In conclusion, we confirmed that H pylori-negative gastritis was present in approximately 18% of patients with gastritis. PPI use did not explain the risk for H pylori-negative gastritis. It is important to evaluate both the absolute and relative prevalence of non-H pylori-gastritis. As H pylori infection continues to decline, a greater proportion of ulcers will be caused by non-H pylori causes. Even if non-H pylori histologic gastritis is uncommon, it will still represent a large proportion of overall histologic gastritis cases as H pylori prevalence declines. The natural history of H pylori-negative gastritis remains unstudied such that it has the potential to be a progressive disease or associated with clinical outcomes. 
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